Patents Represented by Attorney AstraZeneca AB
-
Patent number: 8349897Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: GrantFiled: December 20, 2010Date of Patent: January 8, 2013Assignee: Astrazeneca ABInventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
-
Patent number: 8329729Abstract: The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.Type: GrantFiled: May 13, 2008Date of Patent: December 11, 2012Assignees: Astrazeneca AB, Pulmagen Therapeutics Synergy Ltd.Inventors: Richard James Bull, Rhonan Lee Ford, Antonio Mete
-
Patent number: 8318752Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.Type: GrantFiled: September 15, 2004Date of Patent: November 27, 2012Assignee: Astrazeneca ABInventor: Bernard Barlaam
-
Patent number: 8314127Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.Type: GrantFiled: July 19, 2006Date of Patent: November 20, 2012Assignee: Astrazeneca ABInventors: Talbir Austin, David O'Sullivan, Matthew Perry, Brian Springthorpe
-
Patent number: 8283361Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: GrantFiled: June 3, 2009Date of Patent: October 9, 2012Assignee: AstraZeneca ABInventors: Allison Laura Choy, Pamela Hill, John Irvin Manchester, Brian Sherer
-
Patent number: 8268841Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.Type: GrantFiled: April 28, 2009Date of Patent: September 18, 2012Assignee: Astrazeneca ABInventors: Nicola Murdoch Heron, Andrew Austen Mortlock, Frederic Henri Jung, Georges Rene Pasquet
-
Patent number: 8258140Abstract: The invention concerns bicyclic compounds of Formula I wherein , R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.Type: GrantFiled: February 9, 2010Date of Patent: September 4, 2012Assignee: Astrazeneca ABInventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
-
Patent number: 8252802Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: June 9, 2011Date of Patent: August 28, 2012Assignee: Astrazeneca ABInventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
-
Patent number: 8247562Abstract: The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by histone deacetylase.Type: GrantFiled: September 10, 2010Date of Patent: August 21, 2012Assignee: Astrazeneca ABInventors: Elaine Sophie Elizabeth Stokes, Craig Anthony Roberts, Michael James Waring
-
Patent number: 8232296Abstract: 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.Type: GrantFiled: February 16, 2010Date of Patent: July 31, 2012Assignee: Astrazeneca ABInventors: Lars-Erik Briggner, Per Tomas Klingstedt, Hans Roland Lönn, Robert Zuban, Marie-Lyne Alcaraz, Robert Anthony Nixon, Andrew James Watts
-
Patent number: 8207193Abstract: The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation (I), (II), (IIIa), (IIIb).Type: GrantFiled: November 13, 2007Date of Patent: June 26, 2012Assignee: Astrazeneca ABInventors: Rhonan Ford, Andrew Mather, Antonio Mete
-
Patent number: 8207202Abstract: The invention concerns benzamide compounds of formula (I), wherein R1 is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C1-4alkyl, C3-4cycloalkyl, C1-4alkoxy and C3-4cycloalkoxy; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).Type: GrantFiled: October 17, 2006Date of Patent: June 26, 2012Assignee: Astrazeneca ABInventors: David Michael Andrews, Elaine Sophie Elizabeth Stokes, Andrew Turner, Michael James Waring
-
Patent number: 8198441Abstract: There is provided a process for the preparation of a compound of Formula 1, the use of said process in the preparation of a compound of Formula 5 or a phosphate, sulphate, hydrogensulphate, malate, citrate, tartrate or fumarate salt thereof, and the use of the fumarate salt in a composition for use in therapy.Type: GrantFiled: June 18, 2009Date of Patent: June 12, 2012Assignee: AstraZeneca ABInventors: Helen Blade, Gwydion Huw Churchill, Angela Charlotte Currie, Benjamin Charles Dobson, Martin Neal Kenworthy, Lyn Powell, Steven Anthony Raw, Peter Samuel Hynes
-
Patent number: 8198285Abstract: The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.Type: GrantFiled: January 18, 2011Date of Patent: June 12, 2012Assignee: Astrazeneca ABInventors: Tao Feng, Hitesh Jayantilal Sanganee, Hiroki Wada
-
Patent number: 8163905Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: June 26, 2008Date of Patent: April 24, 2012Assignee: AstraZeneca ABInventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
-
Patent number: 8153643Abstract: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.Type: GrantFiled: October 7, 2005Date of Patent: April 10, 2012Assignee: AstraZeneca ABInventors: Patrick Ple, Frederic Henri Jung
-
Patent number: 8138183Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.Type: GrantFiled: July 8, 2008Date of Patent: March 20, 2012Assignee: AstraZeneca ABInventor: Kurt Gordon Pike
-
Patent number: 8114881Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.Type: GrantFiled: May 7, 2007Date of Patent: February 14, 2012Assignee: AstraZeneca ABInventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
-
Patent number: 8101623Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I), methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).Type: GrantFiled: October 10, 2008Date of Patent: January 24, 2012Assignee: AstraZeneca ABInventors: Richard William Arthur Luke, Zbigniew Stanley Matusiak
-
Patent number: 7902189Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: August 21, 2007Date of Patent: March 8, 2011Assignee: AstraZeneca ABInventors: Heather Mary Ellen Duggan, Karine Malagu, Frederic Georges Marie Leroux, Niall Morrisson Barr Martin, Keith Allan Menear, Graeme Cameron Murray Smith